A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Description:

This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Sponsor:

Perspective Therapeutics

Contacts:

Markus Puhlmann, MD, MBA

mpuhlmann@perspectivetherapeutics.com

(319) 665-2150

Government Study Link:

NCT05636618 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

🇺🇸 United States

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Principal Investigator

Thorvadur R. Halfdanarson, MD

University of Kentucky

Lexington, Kentucky 40536, United States

Principal Investigator

Lowell Anthony, MD, FACP

University of Iowa Medical Center

Iowa City, Iowa, United States

Principal Investigator

Yusuf Menda, MD

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

Principal Investigator

Jason Starr, MD

Johns Hopkins University

Baltimore, Maryland 21287, United States

Principal Investigator

Lilja Solnes, MD

Washington University School of Medicine

St. Louis, Missouri, United States

Principal Investigator

Richard Wahl, MD

University of Chicago

Chicago, Illinois 60637, United States

Principal Investigator

Chih-Yi Liao, MD

Nebraska Cancer Specialists

Omaha, Nebraska, United States

Principal Investigator

Samuel Mehr, MD

Contact XCancer: 402-991-8468